Description: Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
Home Page: www.tangotx.com
TNGX Technical Analysis
100 Binney Street
Cambridge,
MA
02142
United States
Phone:
857 320 4900
Officers
| Name | Title |
|---|---|
| Dr. Barbara L. Weber M.D. | Pres, CEO & Director |
| Ms. Daniella Beckman CPA | Chief Financial Officer |
| Dr. Alan Huang Ph.D. | Chief Scientific Officer |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Levi Garraway M.D., Ph.D. | Founder |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Douglas J. Barry Esq., J.D. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Mr. John C. Ross M.S. | VP of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5607 |
| Price-to-Sales TTM: | 28.8999 |
| IPO Date: | 2020-09-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |